On October 16, 2023, the market analyst and investment firm Jehoshaphat Research released a report on R1 RCM. Jehoshaphat stated in pertinent part, “[w]e are short RCM. We believe its financial accounting is so misrepresentative, its corporate governance so surprisingly bad, and the reflexivity of its business model so misunderstood that its stock is practically uninvestible today.”
On this news, the price of R1 RCN common stock declined by 8.25% on October 16, 2023.